 |
|
Treatment of ANCA-Associated Vasculitis
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Dr Bosch and colleagues1 conducted a systematic review of treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, including Wegener granulomatosis. However, their article did not discuss the increased incidence of thromboembolic events in patients with Wegener granulomatosis and the possible role of anticoagulation in these patients.
The incidence of thromboembolic events in Wegener granulomatosis is as high as in patients with previous idiopathic venous thromboembolism (7.0 cases/ 100 patient-years vs 7.2 cases/100 patient-years, respectively).2-3 Considering that prophylactic use of warfarin is an effective method of preventing thromboembolic events in patients with previous idiopathic venous thromboembolism,3-4 it is possible that prophylactic anticoagulation may also have a role in patients with Wegener granulomatosis who have no contraindications to warfarin. This may be especially important during disease activity because 81% of thromboembolic events in persons with active Wegener granulomatosis occur during this phase.2 However, this would need to be addressed by . . . [Full Text of this Article]
Alfredo N. C. Santana, MD
alfredonicodemos@hotmail.com
Telma Antunes, PhD;
Carmen S. V. Barbas, PhD
University of Saõ Paulo Medical School
Saõ Paulo, Brazil
RELATED LETTERS
Treatment of ANCA-Associated Vasculitis
Matt P. Wise and Paul Frost
JAMA. 2007;298(23):2739-2740.
EXTRACT
| FULL TEXT
Treatment of ANCA-Associated Vasculitis—Reply
Xavier Bosch, Antonio Guilabert, Gerard Espinosa, and Eduard Mirapeix
JAMA. 2007;298(23):2740.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Systematic Review
Xavier Bosch, Antonio Guilabert, Gerard Espinosa, and Eduard Mirapeix
JAMA. 2007;298(6):655-669.
ABSTRACT
| FULL TEXT
|
